Acadia Pharmaceuticals Files 8-K on Financials

TL;DR

ACADIA filed an 8-K on 5/7/25 for financial updates.

AI Summary

On May 7, 2025, Acadia Pharmaceuticals Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or significant events were detailed in the provided excerpt.

Why It Matters

This filing indicates Acadia Pharmaceuticals is providing updates on its financial performance and condition to the SEC, which is important for investors to monitor.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of financial information and does not appear to contain any immediate negative news or significant changes.

Key Players & Entities

• ACADIA PHARMACEUTICALS INC (company) — Filer
• May 07, 2025 (date) — Date of Report
• 0000950170-25-065672 (filing_id) — Accession Number
• 12830 El Camino Real, Suite 400, San Diego, California 92130 (address) — Principal Executive Offices

FAQ

From the Filing

0000950170-25-065672.txt : 20250507 0000950170-25-065672.hdr.sgml : 20250507 20250507161319 ACCESSION NUMBER: 0000950170-25-065672 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20250507 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250507 DATE AS OF CHANGE: 20250507 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ACADIA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001070494 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 061376651 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-50768 FILM NUMBER: 25921508 BUSINESS ADDRESS: STREET 1: 12830 EL CAMINO REAL STREET 2: SUITE 400 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 858-558-2871 MAIL ADDRESS: STREET 1: 12830 EL CAMINO REAL STREET 2: SUITE 400 CITY: SAN DIEGO STATE: CA ZIP: 92130 8-K 1 acad-20250507.htm 8-K 8-K 0001070494 false 0001070494 2025-05-07 2025-05-07   UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 07, 2025     Acadia Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter)     Delaware 000-50768 06-1376651 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)           12830 El Camino Real, Suite 400   San Diego , California   92130 (Address of Principal Executive Offices)   (Zip Code)   Registrant’s Telephone Number, Including Area Code: (858) 558-2871   N/A (Former Name or Former Address, if Changed Since Last Report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.0001 per share   ACAD   The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐   Item 2.02 Results of Operations and Financial Condition. On May 7, 2025, Acadia Pharmaceuticals Inc. issued a press release announcing its financial results for the three months ended March 31, 2025. A copy of this press release is furnished herewith as Exhibit 99.1. Pursuant to the rules and regulations of the Securities and Exchange Commission, such exhibit and the information set forth therein and in this Item 2.02 have been furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liability under that section nor shall they be deemed incorporated by reference